nx-5948
Small moleculeexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 30, 2021 (NCT05131022)
Timeline
Indications
Studied for
- Healthy Volunteers · Phase 1
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 2
- Lymphoma · Phase 1
- Lymphoma, B-Cell, Marginal Zone · Phase 1
- Lymphoma, Follicular · Phase 1
- Lymphoma, Large B-Cell, Diffuse · Phase 1
- Lymphoma, Mantle-Cell · Phase 1
- Lymphoma, Primary Cutaneous Anaplastic Large Cell · Phase 2
- Waldenstrom Macroglobulinemia · Phase 1
Mechanism of action
- Tyrosine-protein kinase BTKINHIBITOR
BTK inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CN1CCN([C@@H]2CCCN(c3cnc(C(N)=O)c(Nc4ccc(C5CCN(CC6CCN(c7ccc(C(=O)N[C@H]8CCC(=O)NC8=O)nc7)CC6)CC5)cc4)n3)C2)C1=O- Mol. weight
- 806.97 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5558927 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07221500 | Phase 2 | Oct 15, 2025 | Nurix Therapeutics, Inc. |
| NCT06717269 | Phase 1 | Nov 30, 2024 | Nurix Therapeutics, Inc. |
| NCT06691828 | Phase 1 | Nov 1, 2024 | Nurix Therapeutics, Inc. |
| NCT05131022 | Phase 1 | Nov 30, 2021 | Nurix Therapeutics, Inc. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Nurix Therapeutics, Inc. | For profit | 4 | 4 | 2 | 2021 |
1 organizations
Page 1 / 1